1. Guest, read the 'News in Brief' post for w/c 17th June by clicking this link.
    Dismiss Notice

SMCI RAMSAY 2018: “Characterization of Janus kinase (JAK) activation profiles in ME/CFS subgroups”, Lombardi

Discussion in 'BioMedical ME/CFS Research' started by Andy, Oct 10, 2018.

  1. Andy

    Andy Committee Member & Outreach

    Messages:
    6,527
    Likes Received:
    48,501
    Location:
    Hampshire, UK
    Ramsay 2018 award recipient
    https://solvecfs.org/ramsay-2018-meet-prof-vincent-lombardi-phd/
     
    Lidia, merylg, inox and 15 others like this.
  2. Helen

    Helen Senior Member (Voting Rights)

    Messages:
    317
    Likes Received:
    1,472
    Congratulations Prof. Lombardi and your team!

    It looks like we are getting closer to a treatment if the study will show positive results.
     
    merylg, Solstice, MarcNotMark and 7 others like this.
  3. jaded

    jaded Established Member (Voting Rights)

    Messages:
    72
    Likes Received:
    220
    This research follows on from Prof Lombardi’s and Prof Kenny De Meirleir’s (KDM) prior collaborative work on the appearance of pDCs in gut biopsies of ME patients and potential resulting inflammation.

    https://www.ncbi.nlm.nih.gov/m/pubmed/23422476/?i=7&from=De Meirleir, Kenny

    And their humoral immunity profiling work:

    https://www.ncbi.nlm.nih.gov/m/pubmed/27981498/?i=3&from=De Meirleir, Kenny

    Given that KDM is medical director of the WPI (about to be renamed from Nevada Center for Biomedical Reserch - NVCBR) this work has the potential to translate into clinical trials with JAK/STAT inhibitors. Very exciting.
     
    merylg, Solstice, MarcNotMark and 6 others like this.
  4. Dolphin

    Dolphin Senior Member (Voting Rights)

    Messages:
    1,476
    Likes Received:
    7,269
  5. Sasha

    Sasha Senior Member (Voting Rights)

    Messages:
    3,018
    Likes Received:
    19,268
    Location:
    UK
    RAMSAY 2018: MEET PROF. VINCENT LOMBARDI, PHDOCTOBER 9, 2018
    [​IMG]

    [​IMG]

    “Characterization of Janus kinase (JAK) activation profiles in ME/CFS subgroups”

    A project summary as written by Prof. Vincent Lombardi, PhD:

    Several investigators have reported that ME/CFS is characterized by a dysregulation of inflammatory cytokines; small peptides that are critical for cell-to-cell communication.

    When inflammatory cytokines bind to their cognate cellular receptor, a signaling cascade is triggered that ultimately result in the activation of inflammatory response genes. It is likely that this process plays a significant role in the pathophysiology of ME/CFS, as it does with several other inflammatory disease.

    Most hematopoietic cytokine receptor signaling is mediated by a family of tyrosine kinases referred to as Janus kinases (JAKs) and their downstream transcription factors, referred to as STATs (signal transducers and activators of transcription).

    Several diseases that are characterized by chronic cytokine-associated inflammation such as rheumatoid arthritis, multiple sclerosis and systemic lupus erythematosus are being successfully treated or the subject of clinical trials with drugs that inhibit the activation of JAKs.

    In that ME/CFS is also characterized by systemic inflammatory cytokine production, it is reasonable to propose that some of the same drugs that are being used or developed to treat the aforementioned inflammatory diseases, may also be efficacious in treating ME/CFS.

    Therefore, the overarching goal of our study is to identify specific JAK activation profiles of distinct ME/CFS subgroups, thereby addressing the feasibility of using JAK inhibitors to treat ME/CFS.

    Our study may additionally provide compelling evidence to justify conducting clinical trials to evaluate the efficacy of JAK inhibitors for the treatment of ME/CFS.​


    I've broken the text up for ease of reading. The original is here:

    https://solvecfs.org/ramsay-2018-meet-prof-vincent-lombardi-phd/

    @Emily Taylor - Congratulations to Solve on having funded such interesting projects! :) Can I put a plea in for Solve to break up mega-paragraphs on your site where you describe the research? Many PWME have difficulty reading such large blocks of text.
     
    Lidia, merylg, Amw66 and 12 others like this.
  6. alalush

    alalush Established Member

    Messages:
    6
    Likes Received:
    13
    It is very frustrating good JAK1 medications already exist for some time and we still cannot receive
     
    merylg likes this.
  7. Sunshine3

    Sunshine3 Senior Member (Voting Rights)

    Messages:
    529
    Likes Received:
    3,746
    The holy grail, clinical trials!
     
    merylg likes this.
  8. BurnA

    BurnA Senior Member (Voting Rights)

    Messages:
    302
    Likes Received:
    2,414
    Is this true
     
    Hutan and merylg like this.
  9. Jaybee00

    Jaybee00 Senior Member (Voting Rights)

    Messages:
    148
    Likes Received:
    504
  10. eva luna

    eva luna Established Member

    Messages:
    5
    Likes Received:
    41
    Is there any news on this trials? Or when is some news expected?
     
  11. Snowdrop

    Snowdrop Senior Member (Voting Rights)

    Messages:
    823
    Likes Received:
    5,231
    I could not find any specific time frame. The profile is from October 2018 so I think not for some time to come.
     
  12. alalush

    alalush Established Member

    Messages:
    6
    Likes Received:
    13
    Meirleir is going to do an official trial in 6 months with 3 groups (Filgotinib, another JAK1 inhibitor and placebo). Filgotinib will be first available on the market in BENELUX (Belgium, Netherlands, Luxembourg) around May 2020. Price range will be around 10.000euro/year/patient according to the CEO from Galapagos. But of course if trials are succesful hopefully refunds via local governments will be possible. Meirleir says it will bring many patients into remission but I am awaiting trial results first... I stay sceptic but optimistic. Currently there are many JAK1 inhibitors in the pipeline so there is competition which is a good thing.
     
    Inara, Sunshine3, Helen and 4 others like this.

Share This Page